[1]王 健,宁 莉,汪国平.甲泼尼龙联合羟基脲治疗原发性膜性肾病的疗效[J].医学信息,2020,33(01):137-139.[doi:10.3969/j.issn.1006-1959.2020.01.043]
 WANG Jian,NING Li,WANG Guo-ping.Effect of Methylprednisolone Combined with Hydroxyurea in the Treatment of Primary Membranous Nephropathy[J].Medical Information,2020,33(01):137-139.[doi:10.3969/j.issn.1006-1959.2020.01.043]
点击复制

甲泼尼龙联合羟基脲治疗原发性膜性肾病的疗效()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年01期
页码:
137-139
栏目:
药物与临床
出版日期:
2020-01-01

文章信息/Info

Title:
Effect of Methylprednisolone Combined with Hydroxyurea in the Treatment of Primary Membranous Nephropathy
文章编号:
1006-1959(2020)01-0137-03
作者:
王 健宁 莉汪国平
(赣南医学院第一附属医院肾内科,江西 赣州 341000)
Author(s):
WANG JianNING LiWANG Guo-ping
(Department of Nephrology,the First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi,China)
关键词:
甲泼尼龙羟基脲环磷酰胺膜性肾病
Keywords:
MethylprednisoloneHydroxyureaCyclophosphamideMembranous nephropathy
分类号:
R96
DOI:
10.3969/j.issn.1006-1959.2020.01.043
文献标志码:
A
摘要:
目的 探讨甲泼尼龙联合羟基脲治疗原发性膜性肾病的临床效果。方法 选取2016年1月~2018年12月我院经肾穿刺活检病理确诊为原发性膜性肾病患者42例,按照随机数字表法分成观察组(20例)和对照组(22例)。观察组给予甲泼尼龙联合羟基脲治疗,对照组接受甲泼尼龙联合环磷酰胺治疗,比较两组24h尿总蛋白、血浆白蛋白、临床疗效及并发症发生率。结果 两组治疗前后24h尿总蛋白、血浆白蛋白比较,差异无统计学意义(P>0.05);观察组总有效率为80.00%,低于对照组的86.36%,但差异无统计学意义(P>0.05)。观察组并发症总发生率为35.00%,低于对照组的40.91%,但差异无统计学意义(P>0.05)。结论 甲泼尼龙联合环磷酰胺治疗原发性膜性肾病较甲泼尼龙联合羟基脲降尿蛋白效果具有非劣效性,且无严重并发症发生,可作为治疗的备选方案。
Abstract:
Objective To investigate the clinical effect of methylprednisolone combined with hydroxyurea in the treatment of primary membranous nephropathy. Methods From January 2016 to December 2018, 42 patients with primary membranous nephropathy confirmed by renal biopsy in our hospital were randomly divided into observation group (20 cases) and control group (22 cases). The observation group was treated with methylprednisolone combined with hydroxyurea, and the control group was treated with methylprednisolone combined with cyclophosphamide. The 24h urine total protein, plasma albumin, clinical efficacy, and complication rate were compared between the two groups. Results There was no significant difference in urine total protein and plasma albumin between the two groups before and after treatment for 24 h (P>0.05);The total effective rate in the observation group was 80.00%, which was lower than 86.36% in the control group, but the difference was not statistically significant (P>0.05). The total incidence of complications in the observation group was 35.00%, which was lower than 40.91% in the control group, but the difference was not statistically significant (P>0.05). Conclusion Methylprednisolone combined with cyclophosphamide for primary membranous nephropathy has a non-inferior effect compared with methylprednisolone combined with hydroxyurea, and no serious complications occur. It can be used as an alternative treatment option.

参考文献/References:

[1]Couser WG.Primary Membranous Nephropathy[J].Clin J Am Soc Nephrol,2017,12(6):983-997. [2]Cattran DC,Brenchley PE.Membranous nephropathy:integrating basic science into improved clinical management[J].Kidney Int,2017,91(3):566-574. [3]Chen Y,Schieppati A,Chen X,et al.Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome[J].Cochrane Database Syst Rev,2014(10):D4293. [4]骆琳,刘建华,吴丽娜.特发性膜性肾病预后影响因素的研究进展[J].中华肾脏病杂志,2019,35(1):70-76. [5]Hundemer GL,Rosales IA,Chen YB,et al.Hydroxyurea for Treatment of Nephrotic Syndrome Associated With Polycythemia Vera[J].Am J Kidney Dis,2016,68(3):465-468. [6]Bartolucci P,Habibi A,Stehle T,et al.Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease[J].J Am Soc Nephrol,2016,27(6):1847-1853. [7]Mercadal L.Membranous nephropathy[J].Nephrol Ther,2013,9(7):507-517. [8]Ponticelli C,Escoli R,Moroni G.Does cyclophosphamide still play a role in glomerular diseases[J].Autoimmun Rev,2018. [9]Agrawal RK,Patel RK,Shah V,et al.Hydroxyurea in sickle cell disease: drug review[J].Indian J Hematol Blood Transfus,2014,30(2):91-96. [10]刘洁,陈哲,张斌,等.羟基脲联合小剂量肠溶阿司匹林治疗真性红细胞增多症的疗效及对凝血功能的影响[J].湖南师范大学学报(医学版),2017,14(5):20-23. [11]Laurin LP,Nachman PH,Desai PC,et al.Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease[J].Nephrol Dial Transplant,2014,29(6):1211-1218.

相似文献/References:

[1]赵俊芝,赵永强,梁 曼.甲泼尼龙联合阿奇霉素治疗难治性支原体肺炎患儿的 临床效果分析[J].医学信息,2018,31(07):131.[doi:10.3969/j.issn.1006-1959.2018.07.044]
 ZHAO Jun-zhi,ZHAO Yong-qiang,LIANG Man.Analysis of the Clinical Effect of Methylprednisolone Combined with Azithromycin in Treatment of Children with Refractory Mycoplasma Pneumonia[J].Medical Information,2018,31(01):131.[doi:10.3969/j.issn.1006-1959.2018.07.044]
[2]易晓明,曾 芬.甲泼尼龙治疗SCAP的效果及其对降钙素原水平的影响[J].医学信息,2019,32(21):145.[doi:10.3969/j.issn.1006-1959.2019.21.047]
 YI Xiao-ming,ZENG Fen.Effect of Methylprednisolone on SCAP and its Effect on Procalcitonin Level[J].Medical Information,2019,32(01):145.[doi:10.3969/j.issn.1006-1959.2019.21.047]
[3]陈艳丽.甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的疗效与安全性的Meta分析[J].医学信息,2020,33(06):96.[doi:10.3969/j.issn.1006-1959.2020.06.028]
 CHEN Yan-li.Meta-analysis of the Efficacy and Safety of Methylprednisolone Combined with Azithromycin in the Treatment of Refractory Mycoplasmal Pneumonia in Children[J].Medical Information,2020,33(01):96.[doi:10.3969/j.issn.1006-1959.2020.06.028]
[4]喻 明,李 莹,王秀容.甲泼尼龙联合丙种球蛋白治疗抗NMDAR型脑炎的疗效及对患者精神症状的影响[J].医学信息,2021,34(15):159.[doi:10.3969/j.issn.1006-1959.2021.15.044]
 YU Ming,LI Ying,WANG Xiu-rong.Efficacy of Methylprednisolone Combined with Gamma Globulin in the Treatment of Anti-NMDAR Encephalitis and Its Effect on Patient’s Mental Symptoms[J].Medical Information,2021,34(01):159.[doi:10.3969/j.issn.1006-1959.2021.15.044]
[5]金 英.血浆置换联合大剂量甲泼尼龙对特发性血小板减少性紫癜患者血小板相关免疫球蛋白及T细胞亚群的影响[J].医学信息,2022,35(09):131.[doi:10.3969/j.issn.1006-1959.2022.09.032]
 JIN Ying.Effect of Plasma Exchange Combined with High-dose Methylprednisolone on Platelet-related Immunoglobulin and T Cell Subsets in Patients with Idiopathic Thrombocytopenic Purpura[J].Medical Information,2022,35(01):131.[doi:10.3969/j.issn.1006-1959.2022.09.032]

更新日期/Last Update: 2020-01-01